Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series*

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia : a case series*. / Brivio, Erica; Chantrain, Christophe F.; Gruber, Tanja A.; Thano, Adriana; Rialland, Fanny; Contet, Audrey; Elitzur, Sarah; Dalla-Pozza, Luciano; Kállay, Krisztián Miklós; Li, Chi kong; Kato, Motohiro; Markova, Inna; Schmiegelow, Kjeld; Bodmer, Nicole; Breese, Erin H.; Hoogendijk, Raoull; Pieters, Rob; Zwaan, Christian Michel.

I: British Journal of Haematology, Bind 193, Nr. 6, 2021, s. 1172-1177.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Brivio, E, Chantrain, CF, Gruber, TA, Thano, A, Rialland, F, Contet, A, Elitzur, S, Dalla-Pozza, L, Kállay, KM, Li, CK, Kato, M, Markova, I, Schmiegelow, K, Bodmer, N, Breese, EH, Hoogendijk, R, Pieters, R & Zwaan, CM 2021, 'Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series*', British Journal of Haematology, bind 193, nr. 6, s. 1172-1177. https://doi.org/10.1111/bjh.17333

APA

Brivio, E., Chantrain, C. F., Gruber, T. A., Thano, A., Rialland, F., Contet, A., Elitzur, S., Dalla-Pozza, L., Kállay, K. M., Li, C. K., Kato, M., Markova, I., Schmiegelow, K., Bodmer, N., Breese, E. H., Hoogendijk, R., Pieters, R., & Zwaan, C. M. (2021). Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series*. British Journal of Haematology, 193(6), 1172-1177. https://doi.org/10.1111/bjh.17333

Vancouver

Brivio E, Chantrain CF, Gruber TA, Thano A, Rialland F, Contet A o.a. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series*. British Journal of Haematology. 2021;193(6):1172-1177. https://doi.org/10.1111/bjh.17333

Author

Brivio, Erica ; Chantrain, Christophe F. ; Gruber, Tanja A. ; Thano, Adriana ; Rialland, Fanny ; Contet, Audrey ; Elitzur, Sarah ; Dalla-Pozza, Luciano ; Kállay, Krisztián Miklós ; Li, Chi kong ; Kato, Motohiro ; Markova, Inna ; Schmiegelow, Kjeld ; Bodmer, Nicole ; Breese, Erin H. ; Hoogendijk, Raoull ; Pieters, Rob ; Zwaan, Christian Michel. / Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia : a case series*. I: British Journal of Haematology. 2021 ; Bind 193, Nr. 6. s. 1172-1177.

Bibtex

@article{f19aedda8d2f41d2b5189a342047ec64,
title = "Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series*",
abstract = "No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.",
keywords = "ALL, infants, inotuzumab ozogamicin",
author = "Erica Brivio and Chantrain, {Christophe F.} and Gruber, {Tanja A.} and Adriana Thano and Fanny Rialland and Audrey Contet and Sarah Elitzur and Luciano Dalla-Pozza and K{\'a}llay, {Kriszti{\'a}n Mikl{\'o}s} and Li, {Chi kong} and Motohiro Kato and Inna Markova and Kjeld Schmiegelow and Nicole Bodmer and Breese, {Erin H.} and Raoull Hoogendijk and Rob Pieters and Zwaan, {Christian Michel}",
year = "2021",
doi = "10.1111/bjh.17333",
language = "English",
volume = "193",
pages = "1172--1177",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia

T2 - a case series*

AU - Brivio, Erica

AU - Chantrain, Christophe F.

AU - Gruber, Tanja A.

AU - Thano, Adriana

AU - Rialland, Fanny

AU - Contet, Audrey

AU - Elitzur, Sarah

AU - Dalla-Pozza, Luciano

AU - Kállay, Krisztián Miklós

AU - Li, Chi kong

AU - Kato, Motohiro

AU - Markova, Inna

AU - Schmiegelow, Kjeld

AU - Bodmer, Nicole

AU - Breese, Erin H.

AU - Hoogendijk, Raoull

AU - Pieters, Rob

AU - Zwaan, Christian Michel

PY - 2021

Y1 - 2021

N2 - No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

AB - No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

KW - ALL

KW - infants

KW - inotuzumab ozogamicin

U2 - 10.1111/bjh.17333

DO - 10.1111/bjh.17333

M3 - Journal article

C2 - 33529389

AN - SCOPUS:85100188201

VL - 193

SP - 1172

EP - 1177

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -

ID: 256723424